Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label, multi-center, dose-escalation study to evaluate the safety, PK,
anti-tumor activity, and pharmacodynamic effects of SL-172154 administered by intratumoral
injection in subjects with cutaneous squamous cell carcinoma (CSCC) or squamous cell
carcinoma of the head and neck (SCCHN).